{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:30:18Z","timestamp":1769761818384,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijrobp.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:18:37Z","timestamp":1682489917000},"page":"400-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-034X","authenticated-orcid":false,"given":"Raymond B.","family":"Mailhot Vega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Harker-Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Forlenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth B.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.04.022_bib0001","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory hodgkin lymphoma: Guidelines from the international lymphoma radiation oncology group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN guidelines insights: Hodgkin lymphoma, version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-Korholz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0004","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: A report from the Children's Oncology Group study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (aethera): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0006","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijrobp.2020.08.055","article-title":"Risk of pneumonitis and outcomes after mediastinal proton therapy for relapsed\/refractory lymphoma: A PTCOG and PCG collaboration","volume":"109","author":"Tseng","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0007","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14338\/IJPT-21-00012.1","article-title":"Evaluating disparities in proton radiation therapy use in AHOD1331, a contemporary children's oncology group trial for Advanced-Stage Hodgkin Lymphoma","volume":"8","author":"Mailhot Vega","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0009","doi-asserted-by":"crossref","first-page":"733","DOI":"10.6004\/jnccn.2021.0027","article-title":"Pediatric Hodgkin lymphoma, version 3.2021","volume":"19","author":"Flerlage","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.12768","article-title":"Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma\u2014Results of the UK HD3 relapse treatment strategy","volume":"165","author":"Shankar","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0011","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin's disease: Results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2019.01.026","article-title":"Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy","volume":"134","author":"Tinkle","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0013","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0014","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.022_bib0016","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.2022016098","article-title":"Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis","volume":"140","author":"Parekh","year":"2022","journal-title":"Blood"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623003814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623003814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T12:02:38Z","timestamp":1725105758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623003814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0360301623003814"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.022","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}